ScreenerHero

PBLS Parabilis Medicines, Inc.

NAS · US · Healthcare · Biotechnology · parabilismed.com
28.82USD-0.14%Mkt Cap: 3.56B $P/E: —

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics thro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.56B USD
Enterprise Value2.49B USD
Revenue (TTM)148.00K USD
Gross Profit-12.95M USD
Net Income (TTM)-145.89M USD
Revenue/Share0.01 USD
Last Price28.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.20
PEG—
EV/EBITDA-14.74
EV/Revenue16837.73
P/S24088.98
P/B3.40
EPS (TTM)-9.51
EPS (Forward)-2.19
52W Range
24.6624% of range42.34
52W High42.34 USD
52W Low24.66 USD
Profitability
Gross Margin0.00%
Oper. Margin-34382.43%
EBITDA Margin0.00%
Profit Margin0.00%
ROE882.89%
ROA-180.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.71M USD
CapEx (TTM)306.00K USD
FCF Margin—
FCF Yield—
Net Debt-1.07B USD
Net Debt/EBITDA6.35
Balance Sheet
Debt/Equity-3.55
Current Ratio17.91
Quick Ratio17.83
Book Value/Sh8.48 USD
Cash/Share9.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)41.75 USD
Upside (mean)+44.9%
Target Range40.00 USD – 45.00 USD
40.00+44.9% to mean45.00
# Analysts4
Ownership
Shares Out.121.95M
Float82.07M
Insiders7.03%
Institutions81.90%
Short Interest
Short Ratio14.2d
Short % Float5.00%
Short % Out.4.93%
Shares Short6.09M
Short (prev mo.)5.26M
Technical
SMA 5036.27 (-20.5%)
SMA 20033.46 (-13.9%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)999.66K
Avg Vol (10d)841.44K
Technical Indicators
RSI (14)32.8
MACD-2.1805
MACD Signal-1.4825
MACD Hist.-0.6979
BB Upper41.78 USD
BB Middle34.07 USD
BB Lower26.36 USD
BB Width45.26%
ATR (14)2.777 USD
Vol Ratio (20d)0.79x